Drug Search Results
More Filters [+]

ASP-4901

Alternative Names: asp-4901, asp4901, asp 4901
Latest Update: 2018-12-24
Latest Update Note: Clinical Trial Update

Product Description

Astellas Pharma was developing asp-4901, an oral PDE9 inhibitor, for the treatment of benign prostatic hyperplasia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02038868)

Mechanisms of Action: PDE9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ASP-4901

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Prostatic Hyperplasia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

4901-CL-0201

P2

Completed

Prostatic Hyperplasia

2014-04-04

24%

Recent News Events

Date

Type

Title